This Week's Citation Classic

CC/NUMBER 38 SEPTEMBER 19, 1983

Lieberman J. Heterozygous and homozygous alpha₁-antitrypsin deficiency in patients with pulmonary emphysema. N. Engl. J. Med. 281:279-84, 1969. [Dept. Respiratory Diseases, City of Hope Med. Ctr., Duarte; Dept. Medicine, Veterans Admin. Hosp., Long Beach; and UCLA Sch. Med., Los Angeles, CA]

Measurement of the serum trypsin inhibitory capacity (STIC) in 39 relatives of a homozygous proband for alpha₁-antitrypsin (a₁AT) deficiency and in 66 patients with pulmonary emphysema at a Veterans Administration hospital revealed that there is an increased prevalence of both homozygous and heterozygous a₁AT deficiency in patients with pulmonary emphysema. [The SCI® indicates that this paper has been cited in over 225 publications since 1969.]

J. Lieberman Veterans Administration Medical Center 16111 Plummer Street Sepulveda, CA 91343

June 23, 1983

"The studies reported in this paper were performed while I was a clinical investigator and section chief at the Long Beach, California, Veterans Administration (VA) Hospital. My research had involved studies of blood and tissue proteolytic enzymes, making me especially interested in the reports by Laurell and Eriksson^{1,2} of an association between severe alpha₁-antitrypsin (α_1 AT) deficiency and pulmonary emphysema. A rhone call informed me of a 50-year-old patient with far advanced pulmonary emphysema and a strong family history of this disease. I rapidly set up an assay to measure the serum trypsin inhibitory capacity (STIC) in this patient, and, as expected, found a severe deficiency of a₁AT. To my delight, 39 relatives were also available for a pedigree study revealing three with documented pulmonary emphysema and STIC levels in the intermediate deficiency range. At that time, only a severe deficiency of a AT was thought to predispose to pulmonary emphysema. However, if an intermediate deficiency also predisposed to the development of emphysema, the number of susceptible individuals in the population would increase from 0.04 to five percent. I therefore undertook an investigation of the STIC levels in patients at the Long

Beach VA Hospital who were coded as having pulmonary emphysema.

"The manner in which I undertook this study was fortuitous; I obtained names and phone numbers from the charts, then called the patients to come to my laboratory from their homes to provide blood samples. By so doing, I inadvertently avoided acutely ill hospitalized patients with severe infection. a₁AT is an acute phase reactant protein whose serum level fluctuates in response to bodily stresses such as acute infection. Had I utilized acutely ill patients, I probably would not have detected the 15.2 percent with intermediate α₁AT deficiency.

"Some investigators who initially attempted to confirm my report failed because they studied hospitalized patients in whom a rise of STIC to low normal had occurred, or they studied patients with emphysema in old age homes. We had found that a_1AT deficiency is seen mostly in younger patients with emphysema so that a study of patients over 60 years of age would discover few with the deficiency.

"The reasons for this article becoming a Citation Classic are: 1) it renewed interest in a₁AT deficiency as a significant predisposing factor to pulmonary emphysema rather than a mere medical curiosity; 2) it initiated an ongoing controversy as to whether the heterozygous, intermediate deficiency state of a1AT actually predisposed to pulmonary emphysema. Current work indicates that an acquired relative deficiency of a1AT can also develop in heavy cigarette smokers (increases neutrophilic elastase and decreases elastase-inhibitory activity) and contribute to the development of pulmonary emphysema.³ If so, the lower baseline levels of α_1AT found in heterozygotes would make them even more prone than others to develop a protease-inhibitor imbalance, so that any argument regarding whether or not an intermediate deficiency of α_1AT may predispose to emphysema in smokers is unwarranted. Thus, I believe that this paper still relays an important and practical message: SMOK-ING IS BAD FOR YOUR LUNGS, ESPECIAL-LY IF YOU INHERIT AN INTERMEDIATE OR SEVERE DEGREE OF a1AT DEFICIEN-CY."4,5

Laurell C B & Eriksson S. Electrophoretic α₁-globulin pattern of serum α₁-antitrypsin deficiency. Scand. J. Clin. Invest. 15:132-40, 1963.

Serum a₁-antitrypsin in families with hypo-a₁-antitrypsinemia.
Clin. Chim. Acta 11:395-8, 1965.

Isnoff A & Dearing R. Alpha₁-proteinase inhibitor is more sensitive to inactivation by cigarette smoke than is leukocyte elastase. Amer. Rev. Resp. Dis. 126:691-4, 1982.

Gelb A F, Klein E & Lieberman J. Pulmonary function in nonsmoking subjects with alpha₁-antitrypsin deficiency (MZ phenotype). Amer. J. Med. 62:93-8, 1977.

Lieberman J, Galdulis L & Roberts L. Racial distribution of α₁-antitrypsin variants among junior high school students. Amer. Rev. Resp. Dis. 114:1194-8, 1976.